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Expanding whole blood sample collection for transcriptome analysis beyond
traditional phlebotomy clinics will open new frontiers for remote immune
research and telemedicine. Determining the stability of RNA in blood samples
exposed to high ambient temperatures (>30°C) is necessary for deploying
home-sampling in settings with elevated temperatures (e.g., studying
physiological response to natural disasters that occur in warm locations or in
the summer). Recently, we have developed homeRNA, a technology that
allows for self-blood sampling and RNA stabilization remotely. homeRNA
consists of a lancet-based blood collection device, the Tasso-SST™ which
collects up to 0.5 ml of blood from the upper arm, and a custom-built
stabilization transfer tube containing RNAlater™. In this study, we investigated
the robustness of our homeRNA kit in high temperature settings via two small
pilot studies in Doha, Qatar (no. participants = 8), and the Western and South
Central USA during the summer of 2021, which included a heatwave of
unusually high temperatures in some locations (no. participants = 11). Samples
collected from participants in Doha were subjected to rapid external
temperature ﬂuctuations from being moved to and from air-conditioned areas
and extreme heat environments (up to 41°C external temperature during brief
temperature spikes). In the USA pilot study, regions varied in outdoor
temperature highs (between 25°C and 43.4°C). All samples that returned a RNA
integrity number (RIN) value from the Doha, Qatar group had a RIN ≥7.0, a
typical integrity threshold for downstream transcriptomics analysis. RIN values
for the Western and South Central USA samples (n = 12 samples) ranged from
6.9–8.7 with 9 out of 12 samples reporting RINs ≥7.0. Overall, our pilot data
suggest that homeRNA can be used in some regions that experience elevated
temperatures, opening up new geographical frontiers in disseminated
transcriptome analysis for applications critical to telemedicine, global health,
and expanded clinical research. Further studies, including our ongoing work in
Qatar, USA, and Thailand, will continue to test the robustness of homeRNA.
KEYWORDS

home blood sampling, personalized medicine, RNA stabilization, high temperature
sampling, global health
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collection and stabilization of whole blood RNA, for use in
disseminated whole blood transcriptome applications (23).
homeRNA uses a blood collection device, the Tasso-SST™, that
collects capillary blood from the upper arm via a lancet; the
blood collection tube from the Tasso system then interfaces
with a custom engineered stabilizer tube that holds liquid
stabilizer solution (RNAlater™) (23). Previously, we
demonstrated successful stabilization of RNA extracted from
samples collected with homeRNA in 47 participants in 10
USA states in a pilot feasibility study for validation of
homeRNA for remote blood collection and RNA stabilization.
However, most of these samples were collected in regions
with relatively moderate summer temperatures or during the
fall/winter and thus we sought to test the homeRNA sampling
kit in regions with elevated temperatures. Our present study
builds on a small body of prior work examining the effects of
blood storage temperature on RNA quality; prior work largely
focused on the effects of cold storage and did not examine
temperatures above 25°C (24–26).
Establishing means to remotely probe the human whole
blood transcriptome in elevated temperature settings has
important implications, including enabling clinical research or
personalized medicine applications in areas with high
temperature and studying diseases/events that are speciﬁc to
warm climates or warm times of year. For example, regions
more highly burdened by tropical diseases would beneﬁt from
a better understanding of the stability of RNA because many
of these areas often have persistently elevated temperatures.
Further, even in regions with more moderate climates for part
of the year, researchers may wish to conduct remote sampling
studies in the summer months, particularly when tied to a
speciﬁc seasonal event. For example, a study aiming to
understand wildﬁre smoke exposure in the Western and
South Central USA would necessitate sampling in the summer
months where temperatures are elevated, as these months are
when wildﬁres occur. Overall, the ability to reliably stabilize
RNA with homeRNA in high temperature settings will open
up remote transcriptome studies to regions with a warmer
climate, whether seasonally or permanently.
We present here two small pilot studies exploring the
application of homeRNA in high temperature settings. In the
ﬁrst pilot study, homeRNA was used by a small group in the
city of Doha, Qatar before the sample was exposed to
simulated shipping conditions of ﬂuctuating temperatures. In
the second study, homeRNA was used at a regional scale,
where participants used homeRNA in their own homes during
the summer months in several Western and South Central
USA states, which included regions that are typically very hot
(e.g., Reno, Nevada and Southern California) as well as the
Paciﬁc Northwest during the June 2021 heat wave. For
samples collected from both studies, we examine quality
control metrics typical to determining suitability of isolated

Introduction
Blood is a useful bioﬂuid for transcriptome analysis, as it is
relatively non-invasive to obtain and provides ample
information for biomarker identiﬁcation and analysis (1).
Consequently, whole blood RNA transcript analysis has
emerged as an avenue for realizing the goals of personalized
medicine (2, 3). Key biomarkers discovered through blood
transcriptomic studies have potential applications in novel
therapeutics and diagnostics (4–8) and have provided new
avenues for disease monitoring of chronic (9, 10),
autoimmune (11, 12), and infectious diseases (13). By
combining home-sampling technologies and transcriptomics,
one can further expand upon these applications, opening up
both biomarker discovery through discovery-based research
studies, and bring applications such as gene expression-based
disease monitoring and diagnostics to home-based tests.
Further, a technology that allows for remote blood
transcriptomics would be enabling for increasing access to
rural, remote, or underserved communities, for both research
studies and telemedicine, and could be a powerful technology
for enhancing global health efforts (2).
Conducting remote blood transcriptomics research presents
several challenges. For example, while blood is relatively noninvasive to collect, conventional blood collection is limited to
phlebotomy. Logistically, relying on phlebotomy for collection
geographically conﬁnes blood collections to clinic/lab
locations or research institutes. Several self-blood collection
technologies have been developed for remote use, including
ﬁngersticks (8), dried blood spots (14–16), and lancet-based
technologies that collect blood from the upper arm (17–21),
such as the Tasso-SST™ device that we use in our homesampling and RNA stabilization kits (including the work in
this manuscript). Another major challenge of remote blood
transcriptomics is stabilization of whole blood RNA to
minimize RNA degradation due to spontaneous degradation
via autohydrolysis or degradation due to the presence of
ribonucleases (22). Toma et al. developed an at-home blood
collection kit that collects 50 µl of capillary blood via
ﬁngerstick and mixes with a proprietary RNA preservative
solution at a 1:4 ratio (8). To test the ability of the RNA
preservative solution to preserve blood transcriptome, Toma
et al. collected blood samples from participants (n = 3) and
stored at ambient temperature (22°C) or −80°C for 0, 7, 14,
and 28 days, with and without shipping. They found high
correlation coefﬁcients between gene expression levels from
the samples in all conditions, demonstrating the efﬁcacy of
the RNA stabilization solution to preserve RNA integrity over
28 days (8).
To address this burgeoning need and develop technology
for higher blood volumes than are possible with ﬁngersticks,
we have recently developed homeRNA, a kit for the self-
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High temperature ﬂuctuations in
homeRNA collected samples: A small
pilot study in Doha, Qatar

RNA for downstream RNA transcript analysis, including the
RNA integrity number (RIN) and total cellular RNA yield. In
both the small pilot study in Qatar, and the small pilot study
in the Western and South Central USA, we found satisfactory
RIN values (RIN ≥7) in the majority of samples (84%, 16 out
of 19 samples), with a RIN of 6.9 in the remaining 3 samples.
Overall, our data demonstrate successful RNA stabilization as
a function of yield and RIN values using homeRNA in high
temperature settings.

Participant recruitment and demographics
Healthy adult volunteers (18 years or older) were recruited
in Doha, Qatar via word of mouth under a protocol approved by
Sidra Medicine Institutional Review Board study number
1609004823. Written informed consent was obtained from all
participants. In total, the study enrolled 8 participants
between the ages of 29 and 53 (7 male and 1 female).

Materials and methods
homeRNA for the collection and
stabilization of whole blood cellular RNA

Temperature ﬂuctuations of homeRNA
collected and stabilized blood samples
Participants were asked to collect and stabilize 1–2 whole
blood samples using homeRNA in a laboratory setting. The
stabilizer vial containing the stabilized blood was placed in
the 50 ml conical tube with the insert provided in the
homeRNA kits (see design and assembly of homeRNA above).
Next the 50 ml tube containing the stabilized blood samples
was placed in a sealed bag (provided in the kit) inside the
homeRNA cardboard package, and then incubated at ambient
temperature (21°C) for 27 h to simulate the amount of time
that might pass between blood collection at home and a
scheduled pickup time from a courier service. Samples 1a
(from participant 1 who was sampled twice) and 2 were
frozen at −80°C after incubation at ambient room
temperature for 27 h. The remaining 6 samples, after 27 h
incubation at ambient temperature, underwent 3 h of
exposure to cycling temperatures in air-conditioned, indoor,
and outdoor environments to simulate shipping conditions of
the homeRNA kit from remote site to lab. Each sample was
exposed to a low of 21°C and a high of 41°C (with the
elevated temperatures occurring as brief temperature spikes,
see Supplementary Table S1 and rationale for this
temperature exposure/study design provided in the Results
and Discussion) over the course of 27–30 h after blood
collection and stabilization.

Design and assembly of homeRNA
The fabrication of the RNA stabilizer tube as an interface to
the Tasso-SST™ blood tube has been described previously (23).
Brieﬂy, the RNA stabilizer tube was designed to hold the
RNAlater™ stabilization solution and connect to the TassoSST™ blood collection tube for remote self-blood collection
and RNA stabilization. The Tasso-SST™ blood collection tube
does not contain an anticoagulant. We previously showed
that Tasso-SST™-mediated capillary blood collection, despite
not having an anticoagulant, did not result in major
compromise of RNA quality as measured by RIN values (23).
At the time of the development of the homeRNA kit, the
Tasso-SST™ was the only commercially available Tasso
product for collecting liquid samples; we note that we do not
use the serum separator tube (SST) feature. The stabilizer
tube was injection molded out of polycarbonate (PC:
Makrolon 2407) by Protolabs, Inc (Maple Plain, MN). Details
of the stabilizer tube components and design ﬁles can be
found in Haack, Lim et al. (23). Prior to assembly of the
stabilizer tube, all components were ﬁrst cleaned via
sonication in 70% ethanol (v/v) for 30 min and air dried. The
stabilizer tube was ﬁlled with 1.3 ml RNAlater™ (Thermo
Fisher) stabilization solution and capped. The stabilizer tube
insert was designed to hold the stabilizer tube containing
blood in a 50 ml conical tube during transport. The insert
also allows for facile centrifugation of the sample in the
50 ml standard conical tube when it arrives in a laboratory
setting, as it centers and immobilizes the homeRNA sample
tube relative to the 50 ml tube. The insert was injection
molded out of polycarbonate (PC: Makrolon 2407) by
Protolabs, Inc (Maple Plain, MN). All other components
included in the homeRNA blood kit and the Instruction for
Use (IFU) are listed previously (23) and included in the
Supplementary material of this manuscript for easy
reference (Supplementary Appendix 1). All kit components
were placed in a rigid custom design mailer box fabricated
via die-cutting (The BoxMaker, Inc.) (23).
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homeRNA collection during summer
months: A small pilot study in the Western
and South Central USA
Participant recruitment and demographics
Healthy adult volunteers (18 years or older) were recruited
from US states that historically experience wildﬁre smoke (i.e.,
the Western USA) via word of mouth under a protocol
approved by University of Washington Institutional Review
Board (STUDY00012463). 11 participants between the ages of
20 and 56 years old were enrolled (4 male and 7 female) and
collected samples used in this study. Note: these samples were
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collection tube, the 50 ml conical tube holding the homeRNA
device was brieﬂy centrifuged 10 s at 50 g. Isolated RNA was
stored at −80°C until ready for further analysis.

collected as part of a larger ongoing study our research group is
performing to investigate the effects of wildﬁre smoke exposure
on inﬂammation. These 12 samples (from 11 participants) were
chosen to capture a range of temperatures including the
warmest temperatures experienced by our participants in
summer 2021. Written informed consent was obtained from
all participants. Participants were located in 7 states, including
California, Nevada, New Mexico, Texas, Oregon, Washington,
and Wyoming. Samples were collected between June and July
of 2021, including samples (n = 2) that were collected during
the June 2021 heat wave in the Paciﬁc Northwest.

Assessment of yield and RNA integrity of total
cellular RNA in the Western and South Central
USA
For the pilot study in the USA, RIN values of the ﬁrst 50 µl
elution were obtained on a Bioanalyzer 2100 (Agilent). The
Agilent 2100 Bioanalyzer uses proprietary, built-in software to
calculate RIN values, which is based on the relative peak
height and shape of the 18S and 28S rRNA fragments in the
resulting electropherogram after separation. All samples were
assessed using the RNA 6000 Nano Kit. Samples with
returned concentrations below the quantitative range (<25 ng/µl)
of the RNA 6000 Nano Kit were further analyzed using the
RNA 6000 Pico kit. For these low concentration samples, only
values provided by the Pico kit were used in the data analysis.
Samples 9–11 had sufﬁcient RNA concentration to be within
the quantitative range of the RNA 6000 Nano Kit (25–500 ng/µl),
whereas RNA concentration from the ﬁrst elution from
samples 1–8 were below this threshold and were therefore
diluted 1:5 with nuclease free water to be within the
quantitative range for the RNA 6000 Pico Kit (50–5,000 pg/µl).
RNA concentration was measured for both isolated RNA
aliquots using a Cytation 5 Multi-Mode Reader (Agilent
Biotek Instruments) with a Take3 Micro-Volume Plate at the
wavelengths of 260, 280, and 320 nm (Supplementary
Figure S4).

Participant blood self-collection and
stabilization
Participants were asked to self-collect and stabilize blood
from their upper arm using the homeRNA blood collection
and stabilization kit. Each participant was also asked to
complete a survey with each collection that included
information about the ambient temperature during collection
and the approximate blood level (see Supplementary
Figure S6). Participants were asked to package their stabilized
blood samples to be returned to the lab for analysis using the
provided return mailer bag (per instructions including
containment in a 50 ml conical tube, plastic bag, and the
homeRNA kit cardboard box). Participants left their sample
outside for pickup between the hours of 12:00 PM and 3:00
PM. All stabilized blood samples were mailed using next day
delivery courier services (United Parcel Service, UPS).
Returned samples were delivered to a −20°C freezer and
subsequently stored at −80°C prior to RNA extraction.

Temperature data collection

Assessment of yield and RNA integrity of total
cellular RNA in Qatar

Participants were provided with a temperature monitor
(ThermPro) and were asked to record the temperature at the
time of sampling to obtain the indoor temperature data
(Figure 3Bi). We collected the maximum temperature from
the day the sample was picked up as the outdoor high on
pickup day (Figure 3Bii). Temperature data was obtained
from the daily high reported from the closest weather station
on the day of the pickup. The weather station data was
obtained from Weather Underground.

For the pilot study in Qatar, RNA integrity number (RIN)
values and RNA concentration of the ﬁrst 50 µl elution were
obtained on a Bioanalyzer 2100 (Agilent) using the RNA 6000
Nano Kit (Agilent) for all samples. For samples analyzed in
Qatar, additional assays on the Pico kit were not performed
on samples with concentrations below the qualitative range of
the Nano kit. The bioanalyzer was used to obtain the RNA
concentration from the ﬁrst 50 µl elution of the RNA isolation
protocol (Supplementary Figure S2).

RNA isolation and assessment of RNA
integrity from homeRNA-stabilized whole
blood

Results and discussion
homeRNA at high temperatures: An
overview of two pilot studies

RNA isolation
For both small pilot studies in Doha, Qatar and the Western
and South Central USA, total cellular RNA was isolated using
the Ribopure™ - Blood RNA Isolation Kit (Thermo Fisher)
according to manufacturer’s protocol and eluted in two 50 µl
aliquots. Prior to removing the stabilized blood from the

Frontiers in Digital Health

In this work, we tested the robustness of the homeRNA kit
by evaluating the stability of RNA transcripts in blood collected
using the homeRNA kits during high temperatures in the
summer months (July-August) in two different regions: Doha,
Qatar (in-lab collection with homeRNA, followed by in-ﬁeld
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collecting, stabilizing, shipping, and processing homeRNA
blood samples is outlined in Figure 1, including a schematic
of how a user can collect and stabilize blood with homeRNA.
In each case, our study design was chosen based on how at-

sample exposure in a hot car to simulate conditions in a courier
service) and the Western and South Central USA (remote
collection with homeRNA by participants in their home,
shipped back to the lab). A typical logistical process of

FIGURE 1

Typical process for using homeRNA from collection to processing of samples. (A) Collection and stabilization of blood using homeRNA. (i) Process of
collecting blood from the upper arm with Tasso device and stabilizing the sample with the homeRNA custom stabilizer tube. Image was reprinted
with permission from Haack, Lim et al. homeRNA: A Self-Sampling Kit for the Collection of Peripheral Blood and Stabilization of RNA. Anal. Chem.
2021, 93, 39, 13196–13203. Copyright 2021 American Chemical Society (23). (ii) Map depicting locations of participants in the small pilot studies
conducted in Qatar and the Western and South Central USA. Note, participants in Qatar collected samples themselves in a lab setting. (iii)
illustration demonstrating a participant connecting the Tasso blood tube and the homeRNA stabilizer tube, (iv) homeRNA kit on a coffee table,
depicting a home setting for blood collection. (B) Illustration demonstrating two possible locations where samples may be exposed to high
temperatures including (i) located on a front porch waiting to be picked up (which was the pickup location for many participants in the Western
and South Central USA pilot study) and (ii) in transit in a delivery truck or courier service. (C) ﬁnal step of sample processing for downstream
analysis in a laboratory setting.
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stabilization with the homeRNA kit, each sample was
incubated at room temperature (21°C) for 27 h, simulating
time between remote blood collection and next-day sample
pick up for shipment. After sitting out at room temperature,
the stabilized blood samples were then exposed to ﬂuctuating
external temperatures in air-conditioned, indoor, and outdoor
environments, as outlined in Figure 2A and Supplementary
Table S1, by driving the samples around Doha in a car. This
setup mimics the change in environment and temperatures
that the stabilized blood samples would experience in transit
using a typical courier service (see rationale for design
described at the beginning of the Results and Discussion).
The samples underwent external changes in temperature
between 21°C and 41°C over the course of three hours before
storage at −80°C until the time of analysis (Figure 2A). Of
the 8 participants, stabilized blood samples from 7 of the
donors were exposed to these high environmental temperature
spikes. Samples 1 and 2a (from participant 2 who was
sampled twice: 2a for control and 2b for temperature stress)
were frozen after overnight incubation at room temperature to
serve as controls.
The quality of isolated RNA from all 9 blood samples (from
8 participants) was assessed to observe if the high external
temperature spikes had adverse effects on the RNA stability in
the homeRNA platform. Of the 9 samples, 7 yielded scorable
RIN values (Figure 2C). The two that did not yield a RIN
value (participants 6 and 8) both reported collected blood
volumes of ∼100 µl. We note that blood volume does not
necessarily correlate with RNA yield (see Supplementary
Figure S5) and that variability in blood volume could result
from device-to-device variability in the Tasso blood collection
system and inaccuracy in participant reporting of the volume
of collected blood. These two samples had low RNA
concentrations beneath the limit of detection of the RNA
6000 Nano Kit (<5 ng/µl), but distinct 18S and 28S rRNA
bands are noted in the digital gel (Figure 2B). The scorable
RNA samples had RIN values between 7.6–8.7, demonstrating
a sample quality suitable for downstream transcriptome (e.g.,
RNA-seq) analysis. Electropherograms obtained from the
bioanalyzer can be found in the SI (Supplementary
Figure S1). RNA concentrations for the ﬁrst 50 µl elution
were also obtained with the bioanalyzer (Supplementary
Figure S2). For the 5 samples that were exposed to
temperature ﬂuctuations and yielded a scorable RIN value, the
RNA concentrations from the ﬁrst 50 µl elution ranged from
21 ng/µl to 40 ng/µl (1,050–2,000 ng total cellular RNA in the
ﬁrst 50 µl elution). The two samples that yielded a
concentration less than the qualitative range (5 ng/µl) of the
Nano 6000 kit (participant 6 and 8) both measured a
concentration of 4 ng/µl (200 ng total cellular RNA in the ﬁrst
50 µl elution). Therefore, all samples, including the low
concentration samples (participant 6 and 8), likely had at
least 200 ng total yield of RNA in the ﬁrst elution. In general,

home clinical research studies would be performed in that
region (i.e., a 3-hour car ride to simulate a courier service in
Doha and overnight shipping via UPS in the USA).
Speciﬁcally, in the Qatar pilot study we were interested in
understanding if stabilized blood samples exposed to high
temperature ﬂuctuations in a region of the world that
regularly experiences high temperatures would affect the
quality of isolated blood RNA. The Qatar samples were
collected in a laboratory setting which was air conditioned (to
model the air-conditioned home environment typical in
Qatar) and deliberately stressed in different temperature
environments (i.e., collection at air-conditioned ambient
temperature, exposure to external outdoor high temperatures,
transportation conditions, etc. (Supplementary Table S1)) to
simulate shipping conditions that typically occur between
remote blood collection and shipment back to the lab for
analysis in Qatar. In Qatar, air conditioning is prevalent, and
therefore samples may go from air-conditioned areas to
extreme heat during shipping. Further, in Doha courier
services (such as Uber) are a common method of moving
packages around the city. The conditions we employed
(Supplementary Table S1) were chosen to mimic a typical
car ride that the samples would experience in a courier
service for shipments within the city itself; the length of the
car ride (3 h) is shorter than the time required to ship
packages in the USA with UPS, but is relevant for courier
services in Doha. Subsequently, the Western and South
Central USA pilot study experienced real-world shipping
conditions, in which participants were mailed homeRNA kits
from Seattle, WA to various states in the Western region of
the USA during the summer (Table 1), yielding data from
participants in a range of regions and temperatures to further
test the applicability of homeRNA in multiple high
temperature environments.
The robustness of the homeRNA kit to elevated ambient
temperature exposures was validated by assessing isolated
blood RNA quality with RNA integrity number (RIN)
values. RIN values range between 1 and 10, with 1
referring to a completely degraded sample and 10 referring
to an intact sample (27). RIN values ≥7.0 are standard QC
cut-offs for genome wide transcriptional proﬁling (28).
However, useful RNA sequencing data can still be
obtained from more degraded samples (RIN values between
4 and 7) (29).

homeRNA for high temperature regions:
A pilot study in Doha, Qatar
To understand the robustness of the homeRNA device for
use in clinical studies performed in Doha, Qatar, 8
participants in Doha, Qatar collected and stabilized their own
blood in late August 2021. After blood collection and
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homeRNA for high temperature seasons:
A pilot study in Western and South
Central USA

500 ng is a comfortable minimal cutoff value for large-scale
transcriptomics analyses such as standard RNA-Seq (with
many facilities accepting lower amounts of RNA), and 100 ng
is a comfortable minimal cutoff value for expression analyses
of a small panel of targeted genes. For RNA-Seq, we note that
different cutoff values exist (for example as low as 10–30 ng)
depending on the method and whether cDNA ampliﬁcation is
performed.
The successful isolation and high quality of RNA from
blood samples collected, stabilized, and analyzed in Doha
suggests that the homeRNA platform can be used for at-home
clinical studies in Doha or places similar to Doha, a hot
climate where air conditioning is commonplace in buildings
and vehicles and fast courier services are available. In this
setting, samples experience exposure to short term, high
temperature ﬂuctuations in external environmental conditions.
Perhaps some researchers would assume that rapid
temperature spikes would not affect the quality of RNAlater™stabilized RNA, but we felt that it was necessary to conduct
this ﬁeld testing before using homeRNA for clinical research
in Doha. One important note regarding the experimental
setup for this small pilot study is that the reported
temperatures (Figure 2A, Supplementary Table S1) are that
of the local external environment (i.e., temperature inside the
car, ambient outdoor temperature, etc.) rather than the
temperature of the blood sample itself. It is possible that even
though the external temperatures ﬂuctuated markedly over the
course of three hours with intervals of rapid but short
increases or decreases in ambient temperatures, the blood
sample itself may not have fully equilibrated to these observed
external temperatures. Further experimentation, such as in-lab
controlled temperature stress experiments, could further
determine how spikes in external temperature affect the
temperature of the blood sample itself.

To further assess the robustness of the homeRNA kit in high
temperature settings, 11 participants in various regions
throughout the Western and South Central USA collected and
stabilized their own blood and shipped it back to our lab for
analysis. These samples were collected during the summer of
2021, which involved unusually high temperatures in some
locations, and 2 of these samples were collected during the
June 2021 heatwave in the Paciﬁc Northwest region. Samples
were collected at indoor ambient temperatures ranging
between 21°C and 27°C (Table 1, Figure 3Bi). Typically,
stabilized blood samples were shipped back the same day or
the following day with overnight shipping. The logistics of the
study were such that participants left their package in a
designated pickup area; all participants chose to have their
samples picked up from outside their homes; therefore, all the
stabilized blood samples were also exposed to the outdoor
ambient temperatures following indoor collection and
stabilization (See Table 1 for pickup location). The duration
of post-collection specimen storage prior to transit back to the
lab (turnover duration) can be highly variable; this ranges
from immediate transit (direct package handover a courier
service driver) to overnight storage, in which these specimens
can experience prolonged exposure to high ambient
temperatures. This turnover duration is an important variable
in temperature-dependent specimen stability and our data
reﬂects the cumulative effect of variations in turnover
duration experienced during real-world transits.
According to the day that each sample was collected and
stabilized, the maximum outdoor temperature (“daily high”)
reported for the corresponding location of each participant

TABLE 1 Participant and sampling information for the Western and South Central USA pilot study.

Participant

Self-reported
blood volume
(µl)

Indoor temperature
at sampling (°C)

Outdoor temperature
high on pickup day
(°C)

1A

200

25.0

1B

300

2

400

3

Location of
sampling

Month of
sampling

Total
yield
(µg)

RIN

42.3

Albany, OR

Late June

0.7

6.9

26.3

35.6

25.8

36.8

Albany, OR

Early July

0.8

6.9

Davis, CA

Late July

1.1

300

23.2

7.1

28.7

Seattle, WA

Early August

0.8

4

300

7.4

24.0

33.4

Dallas, TX

Early July

0.7

7.3

5
6

200

23.1

35.3

Laramie, WY

Late July

0.5

7.6

200

24.5

34.8

Pasadena CA

Mid July

0.8

6.9

7

300

26.9

43.4

Portland, OR

Late June

0.5

7.4

8

400

27.2

32.3

Reno, NV

Early August

1.0

7.3

9

300

21.2

25.0

Albuquerque, NM

Late June

1.9

8.2

10

400

25.0

35.4

Portland, OR

Late July

1.8

7.6

11

400

23.0

25.5

Portland, OR

Late July

1.6

8.7
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(based on local weather reports found at Weather
Underground) is included in Table 1. These outdoor
temperatures spanned between 25°C and 44°C (Table 1,
Figure 3Bii). We note that we do not know if the sample was
outside during the daily high and further note that it is
possible that the package was exposed to temperatures higher
than the daily high, such as if it was placed in direct sunlight
or if the temperature inside the pickup vehicle exceeded the
daily high. Thus, the daily high is simply provided as a
reference. In addition to the above, as noted in the Doha pilot
study, the temperature of the blood sample may be different
from the temperature of the external environment.
The quality of isolated RNA from 12 blood samples (from
11 participants) was assessed to observe how various
temperature exposures (indoor, outdoor, shipping conditions,
etc.) affected homeRNA stability in a ﬁeld test. 75% of the
samples (9 out of 12 samples) yielded a RIN ≥7.0 (7.1–8.7)
and the remaining yielded a RIN of 6.9 (Figure 3A). The RIN
values demonstrate sufﬁcient RNA quality for downstream
transcriptomic analysis.
To observe how temperature at the time of collection and
shipment affected the RNA integrity, RIN values were plotted
against the respective indoor temperature at the time of
collection and stabilization (Figure 3Bi) along with the local
weather reports maximum outdoor temperature (Figure 3Bii).
Indoor temperatures reported for the 12 samples range from
21.2–27.2°C. Indoor temperature at the time of collection (at
least across the temperature range and small sample size used
in this study) does not have a clear inﬂuence on the RIN
value. Notably, there is overlap between the indoor
temperatures reported here (Figure. 3B) and in our initial
homeRNA feasibility study (23). In our previous pilot study
conducted in 2020 (23), the majority of the samples were
collected with an ambient indoor temperature between 18–25°
C (n = 43/53 analyzed returned samples where participants
completed their surveys and provided indoor temperature
data), with the other 9 samples ranging from 26–28°C, with 5
at 26°C, 1 at 27°C and 3 at 28°C. The results from the present
study conducted in 2021 with respect to indoor temperature
are plotted together with the results from our 2020 pilot study
(23) with regards to RIN (Supplementary Figure S5Ai) and
total RNA yield (Supplementary Figure S5Bi), in the
supporting information. There is also some overlap in the
range of outdoor highs on pickup day in this study and our
previous study conducted in 2020, but the samples collected
in the 2021 study described here in the Western and South
Central USA were picked up on days with a warmer outdoor
high, on average. For the 2020 pilot study, the outdoor highs
on pickup day ranged from 9–34.8°C, with a median outdoor
high of 21.4°C, and only 7/60 total samples (collected from 47
total participants) had an outdoor high on the pickup day
>30°C (23). In contrast, the median and range of the outdoor
high on pickup day was higher for the present 2021 study,

FIGURE 2

Quality of isolated RNA from stabilized homeRNA samples exposed
to high external temperature spikes in Doha, Qatar. (A) External
temperature ﬂuctuation experienced by self-collected and
stabilized blood samples after storage at ambient temperature (21°
C) for 27 h. External temperature reached a maximum of 41°C.
Black data points indicate the measured temperature; gray dashed
lines are included to connect the points to guide the eye only
(transitions between temperatures may not be linear). (B) Digital
gel image of RNA isolated from homeRNA blood samples with
corresponding RIN values. Samples 2a and 2b were from the same
participant. Samples 1 and 2a did not undergo temperature
ﬂuctuations (they were frozen down at −80°C after overnight
ambient temperature incubation to use as controls). (C) Scorable
RIN values for each blood sample not exposed (control) and
exposed (temperature ﬂuctuation) to high temperature spikes
along with the reported approximate blood volume collected by
each participant. Participants 6 and 8 yielded too low of a RNA
concentration to be detected using the RNA 6000 Nano kit.
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FIGURE 3

Quality of isolated RNA from stabilized homeRNA samples collected during the summer in the Western and South Central USA. (A) Digital gel image of
RNA isolated from homeRNA stabilized blood samples with corresponding RIN values, with (i) samples diluted 1:5 with nuclease-free water and run
with a RNA 6000 Pico kit and (ii) samples run with a RNA 6000 Nano kit without dilution. Participant 1 contributed two samples, 1a and 1b, that
were collected and stabilized on different days and at different temperatures. (B) (i) RIN values from blood collected and stabilized at different
indoor ambient temperatures during summer and (ii) RIN values according to the outdoor temperature high reported on the day of collection.
Each participant was asked to report the approximate blood volume collected before stabilization based on Supplementary Figure S6 in the
collection survey.

downstream analysis. In longitudinal studies with multiple
collection time points, extremely low yields either due to low
blood volume or low circulating WBCs can lead to exclusion
of speciﬁc time points in the longitudinal data series. These
missing-at-random (MAR) samples can be problematic in
longitudinal studies as they create unbalanced data and biased
estimates (30). However, additional statistical approaches such
as time-course gene set analysis (TcGSA) can be used to
account for such heterogeneity in the dataset (30).
In studies where sampling is done in high temperature
climates and samples are susceptible to variable levels of
temperature-induced degradation, it is crucial that initial
analysis of the genes of interest is performed to determine
how their transcript levels change with respect to poststabilization temperature stress as degradation may not occur
uniformly within the sample (29). Prior to complete sample
stabilization, multiple RNA decay pathways may inﬂuence rate

ranging between 25–43.4°C, with a median of 35.1°C. The RIN
(Supplementary Figure S5Aii) and total RNA yield
(Supplementary Figure S5Bii) from the 2020 and 2021
studies are plotted together with respect to outdoor high on
pickup day in Supplementary Figure S5. All but one of the
samples where a RIN was obtained in our 2020 pilot study
yielded a RIN ≥7.0; the one sample with a RIN <7 was
evaluated to a RIN of 6.8 (23). With regards to the
relationship between the outdoor high and RIN in the present
study, the three samples with the lowest RIN (RIN of 6.9)
correspond to outdoor daily high temperatures ≥34°C;
however, four other samples corresponding to outdoor daily
high temperatures ≥35°C returned RIN values ≥7.0.
Although RIN values were indicated as the main
performance metric in this study, we acknowledge that other
performance metrics (e.g., total yield and RNA concentration)
may be used concurrently to guide sample selection for
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of decay for distinct transcript sets (31). In such studies,
alternative normalization strategies (e.g. using linear model
framework to control for effects of RIN values) may be used
to enable identiﬁcation of biological meaningful expression
signatures (29).
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The ability to remotely collect and stabilize blood will
expand future applications in the ﬁeld of personalized
medicine, particularly for analyzing blood transcriptomes
that can give insight to disease progression/therapy
response, immune response, and biomarker discovery.
However, in order to establish the capability to do this, it is
important to examine how exposure to various temperature
conditions affects RNA stability. In this work, we conducted
two small pilot studies to test the robustness of our
homeRNA at-home self-collection and stabilization blood kit
to successfully preserve RNA integrity in high ambient
temperature environments (>30°C) in two different study
designs. These two pilot studies can inform clinical studies
that could be run in places similar to Doha, Qatar (where
samples are only exposed to short temperature spikes in
transit) and the Western and South Central USA (where
samples are in transit overnight given the regional nature of
the study). We demonstrated that the majority of these
blood samples yielded sufﬁcient RIN (≥7.0), which suggests
the usability of these samples for downstream transcriptome
analyses. Important limitations of the present work include
relatively small sample sizes, although we note that this
work follows on our larger study with 47 participants across
the USA (23). Further, we have several ongoing clinical
studies in the USA, with >1,000 samples collected over the
past year; these studies will eventually add to the literature
on the robustness of homeRNA across the USA through
different seasons. It is also important to study the
performance of homeRNA in tropical climates where
samples will undergo longer transit times and longer
periods of sustained high temperatures than those expected
in Doha; to this end, we have ongoing studies utilizing
homeRNA in urban and rural Thailand. As homeRNA is
applied to diagnosis and monitoring of speciﬁc diseases, it
will be important to analyze the expression of genes of
interest that could be affected by elevated temperatures (i.e.,
transcriptional levels of inﬂammatory genes or diseasespeciﬁc genes) using controlled in-lab experiments prior to
personalized medicine applications. To our knowledge, this
is the ﬁrst study to establish use of homeRNA in sampling
regions experiencing higher ambient temperatures,
representing an initial validation study to extend the use of
homeRNA to warm environments.
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